Company intelligence / Profile preview

Mati Therapeutics

Austin, Texas, United Statesmatitherapeutics.com ↗

Ownership: Private
Employees: ~7
Development stage: Phase 2

Overview

Mati Therapeutics has developed the Evolute® Punctal Plug Delivery System—a minimally invasive device placed in the tear duct to deliver sustained-release medication directly to the eye. The lead program uses this technology to deliver latanoprost for glaucoma and ocular hypertension. The company’s leadership team has deep ophthalmology experience from major industry players. Clinical development appears advanced with at least one program at Phase III/commercial scale-up.

Therapeutic areas: Ophthalmology
Modalities: Drug-device combination (sustained-release drug delivery via punctal plug)Small molecules (e.g., latanoprost)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Evolute PPDS

Phase 2

Indications: Glaucoma, Ocular hypertension, Allergy

Beyond the preview

Go deeper on Mati Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mati Therapeutics.

Explore the full profile